highmark glp-1 coverage Medicaid of and Spending on GLP-1s Employer Health Benefit Trends 2026

Coverage gaps, steep out-of-pocket costs, and payer-imposed roadblocks stall progress before treatment even begins, while stigma, fragmented care, and shifting patient perceptions chip away at long-term adherence

In the OASIS-1 study, 13% of participants (people with obesity without diabetes) receiving oral semaglutide 50 mg experienced altered skin sensation events compared to 1% with placebo - these events were generally mild to moderate in severity, occurred during dose escalation to the higher doses and resolved without requiring permanent treatment discontinuation [21]

Who Might Benefit Most From Each Medication

Doctors tell Fortune that some patients dont like the idea of having to take a drug for the rest of their lives

She will partner with you to develop a tailored surgical plan that prioritizes your safety and results

What matters for shift workers is tying injection to a consistent event rather than a time of day